Provexis plc (PXS)
LSE
Closed
Aug 25, 2026
Day's Range
1.0052 wk Range
0.00618Profile - PXS - Provexis plc
Profile
Mic Code
AIMX
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2
Provexis plc is a public limited company specializing in the development, licensing, and commercialization of innovative functional food ingredients, particularly its proprietary Fruitflow technology. Fruitflow, a natural tomato extract available in syrup and powder forms, helps maintain normal platelet aggregation to support healthy blood flow, reducing the risk of aberrant clotting associated with cardiovascular conditions like heart attacks and strokes. Clinically validated in human trials, it offers effects similar to low-dose aspirin but without side effects, and is the only natural antiplatelet with an approved health claim by the European Food Safety Authority. Provexis plc sells Fruitflow directly to food, beverage, and supplement manufacturers worldwide, alongside products like Fruitflow+ Omega-3 via its e-commerce site and retailers. Founded in 1999 to commercialize research from the Rowett Research Institute, the company listed on AIM in 2005 and is headquartered in Reading, United Kingdom. Key partnerships include long-term supply agreements with DSM Nutritional Products and BYHEALTH for expansion into markets like China, where regulatory approvals for new health claims are advancing. Fruitflow's applications extend to mitigating exercise-induced inflammation, managing blood pressure, countering air pollution effects, and modulating the gut microbiome to reduce cardiovascular risk factors.
Profile Details
Type
Common Stock
Ceo
Mr. Ian Ford BA (Hons) ACA, F.C.A.
Address
2 Blagrave Street
City
Reading
Zip
RG1 1AZ
Country
United Kingdom
Phone
44 7490 391888
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
